Hypera S.A.
Research Hypera S.A. (HM6A) on Bullrun: market cap EUR 2.38B, P/E 7.7, dividend yield 5.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHM6A
- ExchangeF
- CountryBrazil
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 2.38B
- P/E7.7
- Dividend yield5.3%
- Financial periodQ1 2026
- RevenueBRL 2.02B
- Net incomeBRL 347.38M
- Free cash flowBRL 382.48M
- Gross margin60.0%
Valuation Snapshot
latest market cap is EUR 2.38B; P/E is 7.7; dividend yield is 5.3%.
Peer valuation comparison
Latest P/E is 7.68x versus a Healthcare sector median of 24.46x (68.6% below).
Latest dividend yield is 5.32% versus a Healthcare sector median of 2.11% (152.1% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | 1.86 | BRL 1.65B | BRL 9.34B | BRL 12.52B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 2.38B | 7.7 | 5.3% | 0.18 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.18 EUR, yield 5.3%.
About Hypera S.A.
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Hypera S.A.'s market cap?
Hypera S.A.'s market capitalization is EUR 2.38B.
What is Hypera S.A.'s P/E ratio?
Hypera S.A.'s price-to-earnings (P/E) ratio is 7.7.
Does Hypera S.A. pay a dividend?
Hypera S.A. has a dividend yield of 5.3%.
What does Hypera S.A. do?
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands.